Clinical Trial: NCT01101438
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Canadian Cancer Trials Group |
| Information Provided By: | Canadian Cancer Trials Group |
| Last Update Posted: | 2023-09-13 |
Study Overview
Brief Summary
This study is looking at whether Metformin, an agent that is commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether Metformin will work with other therapies to keep cancer from recurring. Health Canada has not approved the sale or use of Metformin to treat breast cancer, although they have approved its use in this clinical trial. Although Metformin is approved by the FDA for the treatment of diabetes, its use in breast cancer is considered investigational.
Official Title
Conditions
Intervention / Treatment
- Drug: metformin hydrochloride
- Other: placebo
Other Study ID Numbers
- MA32
- U10CA077202
- CAN-NCIC-MA.32
- CDR0000669788
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Canadian Cancer Trials Group |
| Information Provided By: | Canadian Cancer Trials Group |
| Last Update Posted: | 2023-09-13 |
Study Overview
Brief Summary
This study is looking at whether Metformin, an agent that is commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether Metformin will work with other therapies to keep cancer from recurring. Health Canada has not approved the sale or use of Metformin to treat breast cancer, although they have approved its use in this clinical trial. Although Metformin is approved by the FDA for the treatment of diabetes, its use in breast cancer is considered investigational.
Official Title
Conditions
Intervention / Treatment
- Drug: metformin hydrochloride
- Other: placebo
Other Study ID Numbers
- MA32
- U10CA077202
- CAN-NCIC-MA.32
- CDR0000669788